Animalcare Group PLC - animal health business - Gets positive opinion from EU Committee for Medicinal Products for Veterinary Use for drug Daxocox, which treats pain and inflammation associated with osteoarthritis, or degenerative joint disease, in dogs. A marketing authorisation decision from the European Commission is expected early in the second 2021 quarter. If approved then the authorisation for Daxocox, the brand name for enflicoxib, will be valid in all EU member states as well as Norway, Liechtenstein and Iceland. An equivalent regulatory review for the UK is taking place "largely in parallel" with the EU schedule and a decision is expected "within the same timeframe".
Chief Executive Jenny Winter: "This is a hugely important step in the journey to market for Daxocox, a product that has the potential to play a leading role in the Animalcare growth story. Subject to final approval, we plan to launch Daxocox across European markets in the second half of 2021 and expect the product to contribute to revenues before the end of the year."
Current stock price: 246.00 pence; up 12% on Thursday
Year-to-date change: up 23%
By Anna Farley; annafarley@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Animalcare Grp (ANCR)